A plasma proteomic atlas of rare genetic neurodevelopmental disorders reveals convergent molecular signatures, neurodegenerative overlap, and a cross-disorder severity index
En palabras de los autores
Rare genetic neurodevelopmental disorders are individually too small for well-powered biomarker studies, and each is typically studied alone. We present a harmonized plasma proteomic resource that treats them together: over 10,000 proteins measured across 27 rare genetic neurodevelopmental disorders and unaffected family members, 26 of them with enough participants for differential abundance analysis, paired with standardized adaptive behaviour phenotypes and released with the full analysis pipeline. Aggregating across disorders makes shared biology visible that single-disorder studies cannot resolve. Genetically distinct disorders converge onto two proteomic clusters separated along a single dominant axis, distinguishing cytoskeletal and vesicle-trafficking proteins from metabolic and hepatic ones; the grouping is independent of gene function and of clinical classification, indicating convergence on shared downstream biology rather than gene-specific pathology. Epilepsy leaves a reproducible plasma signature detectable across disorders and largely independent of genotype, identifying candidate markers of seizure burden that are shared rather than syndrome specific. These proteomes also overlap those of adult neurodegenerative disease: most disorders are enriched against at least one signature of Alzheimer disease, Parkinson disease, frontotemporal dementia or amyotrophic lateral sclerosis, more often inversely than concordantly, placing early-life monogenic disorders on a shared axis with late-onset degeneration. A multivariate severity index built from plasma proteins tracks adaptive communication ability in disorders held out entirely from model training and distinguishes severity among individuals who share a diagnosis rather than only separating disorders from one another. Twenty-four of the prioritised cross-disorder proteins have a recorded drug interaction, several with agents already approved for other indications. Recruitment was concentrated at single sites for a subset of disorders, and results for those disorders are reported separately and descriptively throughout. Collectively, these findings support a shift from single-gene to pathway-based, cross-disorder trial strategies that leverage convergent biomarker panels and mechanistically informed, potentially repurposed interventions.
En palabras simples Resumen con IA
Los investigadores midieron más de 10,000 proteínas en plasma sanguíneo de personas con 27 trastornos neurodesarrollativos genéticos raros y sus familiares no afectados. Diferentes trastornos se agruparon en dos grupos de proteínas a lo largo de un eje principal, separando proteínas de estructura celular de las metabólicas. La epilepsia mostró una firma proteica reproducible entre trastornos que no dependía de genes específicos. La mayoría de los trastornos compartieron patrones proteicos con enfermedades cerebrales del adulto como Alzheimer o Parkinson, a menudo en direcciones opuestas. Un índice de severidad basado en proteínas predijo la capacidad de comunicación en trastornos no utilizados para construirlo y distinguió la severidad entre personas con el mismo diagnóstico.
Escrito por Kimi K2.5 usando solo el abstract de arriba. Jev verificó que cada oración esté respaldada por las oraciones del abstract que cita y eliminó las que no. Pasá el cursor por una oración para ver de dónde sale.
Apareció: jueves, 19 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.